SG11201903771XA - Binding molecules specific for asct2 and uses thereof - Google Patents
Binding molecules specific for asct2 and uses thereofInfo
- Publication number
- SG11201903771XA SG11201903771XA SG11201903771XA SG11201903771XA SG11201903771XA SG 11201903771X A SG11201903771X A SG 11201903771XA SG 11201903771X A SG11201903771X A SG 11201903771XA SG 11201903771X A SG11201903771X A SG 11201903771XA SG 11201903771X A SG11201903771X A SG 11201903771XA
- Authority
- SG
- Singapore
- Prior art keywords
- medlmmune
- gaithersburg
- llc
- way
- medimmune
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
MMBM W O 18/089393 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 17 May 2018 (17.05.2018) WIPOI PCT IiiimmomiolollmonoloolunionionovoimIE (10) International Publication Number WO 2018/089393 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/30 (2006.01) A61K 47/68 (2017.01) G01N 33/574 (2006.01) C07K 16/18 (2006.01) (21) International Application Number: PCT/US2017/060489 (22) International Filing Date: 08 November 2017 (08.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/420,008 10 November 2016 (10.11.2016) US 62/501,923 05 May 2017 (05.05.2017) US (71) Applicant: MEDIMMUNE, LLC [US/US]; One Medlm- mune Way, Gaithersburg, MD 20878 (US). (72) Inventors: PORE, Nabendu; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). BOR- ROK III, Martin, J.; c/o Medlmmune, LLC, One Medlm- mune Way, Gaithersburg, MD 20878 (US). CHOWD- HURY, Partha, S.; c/o Medlmmune, LLC, One Medlm- mune Way, Gaithersburg, MD 20878 (US). MICHELOT- TI, Emil, F.; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). TICE, David, A.; c/o Medlmmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). HOLLINGSWORTH, Robert, E.; c/o Medlmmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). CHANG, Chien-Ying; c/o MedImmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). HURT, Elaine, M.; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). YAO, Nai, Shun; c/o Medlmmune, LLC, One Medlmmune Way, Gaithersburg, MD 20878 (US). (74) Agent: GALVEZ, J., Jason et al.; c/o MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: BINDING MOLECULES SPECIFIC FOR ASCT2 AND USES THEREOF FIG. 1A 4000- =I Normal BM L T_ m 3000- AML BM MM BM E 2000- 1000- 0 , Normal BM AML BM (57) : This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments there- of, used in methods related to cancer stem cells, e.g., binding to a cancer stem cell. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates. In certain aspects, the ASCT2-binding molecules bind specifi- cally to cancer stem cells expressing ASCT2. [Continued on next page] WO 2018/089393 Al MIDEDIMOMOIDEIREIDIONIMEITHEMOVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662420008P | 2016-11-10 | 2016-11-10 | |
US201762501923P | 2017-05-05 | 2017-05-05 | |
PCT/US2017/060489 WO2018089393A1 (en) | 2016-11-10 | 2017-11-08 | Binding molecules specific for asct2 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903771XA true SG11201903771XA (en) | 2019-05-30 |
Family
ID=62110415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903771XA SG11201903771XA (en) | 2016-11-10 | 2017-11-08 | Binding molecules specific for asct2 and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20190367605A1 (en) |
EP (1) | EP3538150A4 (en) |
JP (1) | JP2020503258A (en) |
KR (1) | KR20190083654A (en) |
CN (1) | CN109922832A (en) |
AU (1) | AU2017359155A1 (en) |
CA (1) | CA3042054A1 (en) |
IL (1) | IL266464A (en) |
MA (2) | MA50059A (en) |
SG (1) | SG11201903771XA (en) |
TW (1) | TW201832778A (en) |
WO (1) | WO2018089393A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016352967A1 (en) | 2015-11-10 | 2018-06-21 | Medimmune, Llc | Binding molecules specific for ASCT2 and uses thereof |
CA3112977A1 (en) | 2018-10-19 | 2020-04-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
CA3115136A1 (en) | 2018-10-19 | 2020-04-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
AU2020242747A1 (en) | 2019-03-15 | 2021-09-16 | Medimmune Limited | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer |
ES2930295T3 (en) | 2019-03-29 | 2022-12-09 | Medimmune Ltd | Compounds and conjugates thereof |
US20240123081A1 (en) | 2019-10-25 | 2024-04-18 | Medimmune, Llc | Branched moiety for use in conjugates |
TW202140076A (en) | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | Compounds and conjugates thereof |
KR20220130749A (en) | 2020-01-22 | 2022-09-27 | 메디뮨 리미티드 | Compounds and conjugates thereof |
GB202105186D0 (en) | 2021-04-12 | 2021-05-26 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
GB202105187D0 (en) | 2021-04-12 | 2021-05-26 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
CN114058667A (en) * | 2021-10-14 | 2022-02-18 | 珠海市人民医院 | Method for verifying effect of anticancer drug on colon cancer cells |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7582441B1 (en) * | 2005-10-17 | 2009-09-01 | Celera Corporation | Methods and compositions for treating and diagnosing disease |
EP2389948A1 (en) * | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
US8168586B1 (en) * | 2007-11-21 | 2012-05-01 | Celera Corporation | Cancer targets and uses thereof |
US20110171219A1 (en) * | 2008-09-19 | 2011-07-14 | Fahar Merchant | Treating cancer stem cells using targeted cargo proteins |
JP2012508017A (en) * | 2008-11-07 | 2012-04-05 | ファブラス エルエルシー | Anti-DLL4 antibody and use thereof |
KR20120115511A (en) * | 2010-01-15 | 2012-10-18 | 교와 핫꼬 기린 가부시키가이샤 | Anti-asct2(system asc amino acid transporter type 2) antibody |
US9250230B2 (en) * | 2011-02-01 | 2016-02-02 | Shi V. Liu | Using induced pluripotent stem cells for screening anti-neoplastic agents |
WO2014082083A1 (en) * | 2012-11-26 | 2014-05-30 | Caris Science, Inc. | Biomarker compositions and methods |
AU2016352967A1 (en) * | 2015-11-10 | 2018-06-21 | Medimmune, Llc | Binding molecules specific for ASCT2 and uses thereof |
CN108101989A (en) * | 2016-11-24 | 2018-06-01 | 复旦大学 | For the full people source single domain antibody of people TIM-3 and application |
CN110997714B (en) * | 2017-02-17 | 2024-05-03 | 赛诺菲 | Multispecific binding molecules with specificity for dystrophin proteoglycans and laminin-2 |
TWI800552B (en) * | 2017-11-10 | 2023-05-01 | 新加坡科技研究局 | Il2rbeta/common gamma chain antibodies |
WO2020033702A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
-
2017
- 2017-11-08 US US16/346,612 patent/US20190367605A1/en not_active Abandoned
- 2017-11-08 AU AU2017359155A patent/AU2017359155A1/en not_active Abandoned
- 2017-11-08 EP EP17868894.1A patent/EP3538150A4/en not_active Withdrawn
- 2017-11-08 KR KR1020197016106A patent/KR20190083654A/en unknown
- 2017-11-08 JP JP2019523581A patent/JP2020503258A/en active Pending
- 2017-11-08 MA MA050059A patent/MA50059A/en unknown
- 2017-11-08 WO PCT/US2017/060489 patent/WO2018089393A1/en unknown
- 2017-11-08 SG SG11201903771XA patent/SG11201903771XA/en unknown
- 2017-11-08 MA MA046789A patent/MA46789A/en unknown
- 2017-11-08 CA CA3042054A patent/CA3042054A1/en not_active Abandoned
- 2017-11-08 CN CN201780068387.6A patent/CN109922832A/en active Pending
- 2017-11-08 TW TW106138610A patent/TW201832778A/en unknown
-
2019
- 2019-05-06 IL IL266464A patent/IL266464A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3042054A1 (en) | 2018-05-17 |
EP3538150A4 (en) | 2020-07-08 |
US20190367605A1 (en) | 2019-12-05 |
IL266464A (en) | 2019-07-31 |
EP3538150A1 (en) | 2019-09-18 |
CN109922832A (en) | 2019-06-21 |
AU2017359155A1 (en) | 2019-06-13 |
WO2018089393A9 (en) | 2019-03-21 |
WO2018089393A1 (en) | 2018-05-17 |
KR20190083654A (en) | 2019-07-12 |
MA46789A (en) | 2019-09-18 |
MA50059A (en) | 2019-09-18 |
TW201832778A (en) | 2018-09-16 |
JP2020503258A (en) | 2020-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201903302UA (en) | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201811184UA (en) | Lag -3 binding members | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
SG11201805532XA (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same |